A good deal rests on the race to develop a weight-loss pill that will widen the market beyond today's injectable "fat jabs".

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...